FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1506177854> ?p ?o ?g. }

• W1506177854 endingPage "330" @default.
• W1506177854 startingPage "321" @default.
• W1506177854 abstract "Please cite this paper as: Buhimschi C, Baumbusch M, Dulay A, Lee S, Wehrum M, Zhao G, Bahtiyar M, Pettker C, Ali U, Funai E, Buhimschi I. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio. BJOG 2010;117:321–330. Objective Endoglin, an anti-angiogenic glycoprotein expressed on endothelial cells, has been proposed recently as a biomarker of pre-eclampsia (PE). Given that PE is characterised by an imbalance of angiogenic factors, we sought to determine the clinical utility of urinary soluble endoglin, relative to the soluble fms-like tyrosine kinase 1 to placental growth factor (PlGF) ratio, in the diagnosis of PE during gestation. Design Prospective observational cohort. Setting Tertiary referral university hospital. Population Two hundred and thirty-four pregnant women were enrolled prospectively in the following groups: healthy controls, n = 63; gestational age (GA), median (interquartile range), 33 weeks (27–39 weeks); chronic hypertension, n = 27; GA, 33 weeks (30–36 weeks); mild PE, n = 38; GA, 37 weeks (34–40 weeks); severe PE, n = 106; GA, 32 weeks (29–37 weeks). Methods Free urinary levels of soluble endoglin, soluble fms-like tyrosine kinase 1 and PlGF were measured by sensitive and specific immunoassay. Levels for all urinary analytes were normalised to creatinine. Main outcome measures Urinary soluble endoglin, and the soluble fms-like tyrosine kinase 1 to PlGF ratio. Results In healthy controls, urinary soluble endoglin levels were increased significantly at term relative to those earlier in gestation. Severe PE was characterised by an increased urinary level of soluble endoglin, soluble fms-like tyrosine kinase 1, protein to creatinine ratio and soluble fms-like tyrosine kinase 1 to PlGF ratio compared with all other groups. There was a direct correlation between urinary soluble endoglin and proteinuria that remained after GA correction (R = 0.382, P < 0.001). Urinary soluble endoglin could not differentiate mild PE from severe preterm PE. Overall, soluble endoglin had the ability to discriminate PE from chronic hypertension and healthy controls only in women who were evaluated at <37 weeks of GA. The sensitivity, specificity and accuracy of urinary soluble endoglin alone in the diagnosis of PE or in the identification of women with PE requiring a mandated delivery before 37 weeks of gestation were 70%, 86% and 76%, respectively. These values were inferior to those of the soluble fms-like tyrosine kinase 1 to PlGF ratio (P < 0.001). The addition of urinary soluble endoglin did not improve the diagnostic accuracy of the soluble fms-like tyrosine kinase 1 to PlGF ratio alone. Conclusions We have provided evidence that soluble endoglin is present and elevated in the urine of women who develop preterm PE. Urinary soluble endoglin has only limited ability to determine the severity of PE and to distinguish between PE and chronic hypertension both preterm and at term. Compared with urinary soluble endoglin, the soluble fms-like tyrosine kinase 1 to PlGF ratio remains a better marker of disease presence, severity and outcome." @default.
• W1506177854 created "2016-06-24" @default.
• W1506177854 creator A5014775141 @default.
• W1506177854 creator A5016076918 @default.
• W1506177854 creator A5017544253 @default.
• W1506177854 creator A5023620584 @default.
• W1506177854 creator A5026069239 @default.
• W1506177854 creator A5032822196 @default.
• W1506177854 creator A5036928222 @default.
• W1506177854 creator A5051149026 @default.
• W1506177854 creator A5063778306 @default.
• W1506177854 creator A5069181048 @default.
• W1506177854 creator A5074557229 @default.
• W1506177854 date "2009-11-26" @default.
• W1506177854 modified "2023-10-14" @default.
• W1506177854 title "The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio" @default.
• W1506177854 cites W1523878042 @default.
• W1506177854 cites W1590052782 @default.
• W1506177854 cites W1964537768 @default.
• W1506177854 cites W1965084403 @default.
• W1506177854 cites W1976389829 @default.
• W1506177854 cites W1979119639 @default.
• W1506177854 cites W1998442968 @default.
• W1506177854 cites W1999422736 @default.
• W1506177854 cites W2003555777 @default.
• W1506177854 cites W2003608352 @default.
• W1506177854 cites W2003774981 @default.
• W1506177854 cites W2007801514 @default.
• W1506177854 cites W2009388851 @default.
• W1506177854 cites W2025371221 @default.
• W1506177854 cites W2025469568 @default.
• W1506177854 cites W2026133820 @default.
• W1506177854 cites W2034225161 @default.
• W1506177854 cites W2039583599 @default.
• W1506177854 cites W2042813874 @default.
• W1506177854 cites W2054423301 @default.
• W1506177854 cites W2060372234 @default.
• W1506177854 cites W2068561588 @default.
• W1506177854 cites W2072729738 @default.
• W1506177854 cites W2078412851 @default.
• W1506177854 cites W2084574564 @default.
• W1506177854 cites W2089437140 @default.
• W1506177854 cites W2099198156 @default.
• W1506177854 cites W2105632053 @default.
• W1506177854 cites W2110975139 @default.
• W1506177854 cites W2117664842 @default.
• W1506177854 cites W2117687310 @default.
• W1506177854 cites W2118329681 @default.
• W1506177854 cites W2121556945 @default.
• W1506177854 cites W2137433871 @default.
• W1506177854 cites W2142614652 @default.
• W1506177854 cites W2143180984 @default.
• W1506177854 cites W2333725369 @default.
• W1506177854 cites W4236182870 @default.
• W1506177854 cites W4244433662 @default.
• W1506177854 cites W4251118184 @default.
• W1506177854 doi "https://doi.org/10.1111/j.1471-0528.2009.02434.x" @default.
• W1506177854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19943826" @default.
• W1506177854 hasPublicationYear "2009" @default.
• W1506177854 type Work @default.
• W1506177854 sameAs 1506177854 @default.
• W1506177854 citedByCount "20" @default.
• W1506177854 countsByYear W15061778542012 @default.
• W1506177854 countsByYear W15061778542013 @default.
• W1506177854 countsByYear W15061778542014 @default.
• W1506177854 countsByYear W15061778542015 @default.
• W1506177854 countsByYear W15061778542016 @default.
• W1506177854 countsByYear W15061778542018 @default.
• W1506177854 countsByYear W15061778542019 @default.
• W1506177854 countsByYear W15061778542020 @default.
• W1506177854 countsByYear W15061778542022 @default.
• W1506177854 crossrefType "journal-article" @default.
• W1506177854 hasAuthorship W1506177854A5014775141 @default.
• W1506177854 hasAuthorship W1506177854A5016076918 @default.
• W1506177854 hasAuthorship W1506177854A5017544253 @default.
• W1506177854 hasAuthorship W1506177854A5023620584 @default.
• W1506177854 hasAuthorship W1506177854A5026069239 @default.
• W1506177854 hasAuthorship W1506177854A5032822196 @default.
• W1506177854 hasAuthorship W1506177854A5036928222 @default.
• W1506177854 hasAuthorship W1506177854A5051149026 @default.
• W1506177854 hasAuthorship W1506177854A5063778306 @default.
• W1506177854 hasAuthorship W1506177854A5069181048 @default.
• W1506177854 hasAuthorship W1506177854A5074557229 @default.
• W1506177854 hasConcept C10205521 @default.
• W1506177854 hasConcept C126322002 @default.
• W1506177854 hasConcept C134018914 @default.
• W1506177854 hasConcept C16685009 @default.
• W1506177854 hasConcept C167734588 @default.
• W1506177854 hasConcept C170493617 @default.
• W1506177854 hasConcept C185592680 @default.
• W1506177854 hasConcept C188816634 @default.
• W1506177854 hasConcept C2776871010 @default.
• W1506177854 hasConcept C2777025900 @default.
• W1506177854 hasConcept C2777218350 @default.
• W1506177854 hasConcept C2779184299 @default.
• W1506177854 hasConcept C2779234561 @default.
• W1506177854 hasConcept C2780306776 @default.
• W1506177854 hasConcept C2781197716 @default.

• next